17,261 trials
Prostate Cancer
Primary: Change From Baseline in Body Composition (Lean Body Mass) — 54.93; 57.58; -1.27; -0.60 Kilogram — p=0.1497
Cancer
Primary: The Number of Patients Who Enrolled Completed the Study. — 23; 10 Participants
Scabies
Primary: Mortality Rate for Adult Scabies Mites — 2; 6; 8; 14 Adult mites
Non-small Cell Lung Cancer · EGFR-mutant Lung Cancers
Primary: Osimertinib Maximum Tolerated Dose (MTD) (Phase I) — 80 mg
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
Advanced or Inoperable Gastric Cancer
Primary: Progression Free Survival (PFS) by Investigator Assessment — 3.7; 2.1 Months — p== 0.1428
Painful Diabetic Peripheral Neuropathy
Primary: Change in Mean Average Pain Intensity (NRS) — -1.21; -1.03 units on a scale
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival — 8.8 Months
Amyotrophic Lateral Sclerosis
Primary: Number of Subjects With Serious and Non Serious Adverse Events — 1; 1; 1; 1 Participants
Non-small Cell Lung Cancer
Primary: Phase 1b: Frequency of Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v4.03. — 47; 66; 2; 4 Participants
Hypothalamic Obesity
Primary: Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment — 88.9 percentage of participants — p=<0.0001
Invasive Mucormycosis · Invasive Aspergillosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 29 Participants
Chronic Kidney Disease Mineral and Bone Disorder · Renal Osteodystrophy · Vascular Calcification
Primary: Percent Change in PTH Levels — 0; -54.14; -64.04 percentage of change in PTH levels
Thrombotic Microangiopathies · Atypical Hemolytic Uremic Syndrome · Multiple Organ Dysfunction Syndrome
Primary: Survival — 15 Participants — p=<0.0001
Agitation,Psychomotor · Dementia
Primary: Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score — -5.4; -7.1; -2.9; -6.8 score on a scale — p=0.0813